Dermatology Drugs Global Market Report 2018

1
Dermatology Drugs Global Market Report 2018
Including Dermatology Drugs Covering Johnson
Johnson, Allergan Plc, Galderma S.A, Novartis AG,
GlaxoSmithKline Plc
Feb 2018
2
Reasons to Purchase

• Outperform competitors using accurate up to date
  demand-side dynamics information.
• Identify growth segments for investment.
• Facilitate decision making on the basis of
  historic and forecast data and the drivers and
  restraints on the market.
• Create regional and country strategies on the
  basis of local data and analysis.
• Stay abreast of the latest customer and market
  research findings
• Benchmark performance against key competitors.
• Develop strategies based on likely future
  developments.
• Utilize the relationships between key data sets
  for superior strategizing.
• Suitable for supporting your internal and
  external presentations with reliable high
  quality data and analysis
• Gain a global perspective on the development of
  the market.
• Report will be updated with the latest data and
  delivered to you within 3-5 working days of
  order.
• Scope
• Markets Covered Dermatology Drugs
• Companies Mentioned Johnson Johnson, Allergan
  Plc, Galderma S.A, Novartis AG, GlaxoSmithKline
  Plc
• Countries Brazil, China, France, Germany, India,
  Italy, Japan, Spain, Russia, UK, USA and
  Australia.
• Regions Asia-Pacific, Western Europe, Eastern
  Europe, North America, South America, Middle
  East And Africa
• Time series Five years historic and forecast.

3
Dermatology Drugs Market Characteristics
The dermatology drugs market includes medications
that are used for the treatment of skin
conditions such as dermatitis (including eczema),
rosacea, hyperhidrosis, androgenic alopecia,
onychomycosis, hair loss, acne, immune disorders
(including psoriasis), microbial infections
(bacterial, fungal, and viral), vascular and
pigmented lesion removal, common warts,
seborrheic keratosis, and other skin diseases
The market numbers within this briefing are
restricted to pharmaceutical (drug) treatments
and do not cover biologic treatments for these
conditions which are included in a separate
briefing.
Dermatology drugs used to treat acne include
local anesthetics, cleansers, anti- inflammatory
agents, anti-infectives, emollients, and
astringents. These drugs are available for both
topical (external) use and internal use. These
drugs can be sold as over-the-counter (OTC) as
well as prescription drugs. Major OTC
dermatological drugs include Differin, Lamisil,
Monistat, and Abreva. Some of the major
dermatology prescription drugs include
Clobetasol propionate, Flucinonide, Baxdela,
Siliq, Rhofade. The segments that are covered
include Dermatology Drugs Topical
dermatology drugs are available in a wide range
of In this report market value is defined as
the revenues organizations earn by selling their
goods and services within the specified market,
based on the price at which they sell. Only
goods and services traded between entities are
included. The revenues for a specified geography
are consumption values that is, they are
revenues generated by organizations in the
specified geography within the specified
market, irrespective of where they are produced.
4
(No Transcript)
5
Dermatology Drugs Market Historic Growth
The global dermatology drugs market grew from X
billion in 2013 to X billion in 2017 at a
compound annual growth rate (CAGR) of X. The
chart and table below shows the year-on-year
growth of the global dermatology drugs market
during 2013 2017.
Drivers of the Market Restraints on the Market
6
Dermatology Drugs Market Forecast Growth
The global dermatology drugs market is expected
to grow from XX billion in 2017 to 40 billion
in 2021 at a compound annual growth rate (CAGR)
of XX. Going forward, increase in the number of
indications treated by topical drugs coupled
with increase in acne and rosacea patients will
drive the market for dermatology drugs. The
chart and table below shows the year-on-year
growth of the global dermatology drugs market
during 2017 - 2021.
Drivers of the Market Restraints on the Market
7
Dermatology Drugs Market Regional And Country
Analysis
The Asia Pacific was the largest region in the
dermatology drugs market in 2017, dermatology
drugs for X billion or 38 market share. North
America was the x largest region dermatology
drugs for X billion or X market
share. Western Europe was the x largest region
dermatology drugs for X billion or X market
share.
8
Dermatology Drugs Market Competitive Landscape
The leading competitors in the global dermatology
drugs market are Johnson Johnson, Allergan
Plc, Galderma S.A., Novartis AG, GlaxoSmithKline
Plc. The chart and table below displays the
percentage market share of the top players in
the dermatology drugs market industry.
Johnson Johnson generated revenues of XX
billion for the financial year 2016, an XX
increase from the previous year. Allergan Plc.
generated revenues of XX billion for the
financial year 2016, an XX increase from the
previous year. Galderma S.A. generated revenues
of XX billion for the financial year 2016, an
XX increase from the previous year.
9
Novartis AG generated revenues of XX billion for
the financial year 2016, an XX increase from
the previous year. GlaxoSmithKline Plc. generated
revenues of XX billion for the financial year
2016, an XX increase from the previous
year. Bayer AG generated revenues of XX billion
for the financial year 2016, an XX decrease
from the previous year. LEO Pharma A/S generated
revenues of XX billion for the financial year
2016, an XX increase from the previous
year. Company Profile Johnson
Johnson Overview Johnson Johnson (JJ) was the
largest competitor in the dermatology drugs
market in 2017 with a XX share of the market.
The company is engaged in the development,
manufacturing and marketing of personal
care hygienic products, pharmaceuticals and
surgical equipment. JJ was founded in 1886 and
is headquartered at New Jersey, USA. Products
and Services JJ operates through the following
business divisions The Consumer division
offers The Pharmaceutical division offers
products in The Medical Devices And Diagnostics
division manufactures products used
by Strategy Johnson Johnson aims to grow its
geographic footprint and increase investments in
emerging markets and developed markets such as
Japan. In 2016, the company spent 9.1 billion in
RD.liv With prioritized investments in
internal RD, strategic licensing arrangements,
partnerships and select acquisitions, the
company intends to build a robust product
pipeline for
10
Financial Performance Johnson Johnsons Beauty
section in Consumer division, involved in
dermatology drugs manufacturing, generated
revenues of 3.9 billion for the financial year
2016, a 7.3 increase from the previous year. The
company had market Allergan Plc Overview Product
s and Services Strategy Financial
Performance Galderma S.A Overview Products and
Services Strategy Financial Performance Novartis
AG Overview Products and Services
Strategy Financial Performance GlaxoSmithKline
Plc Overview Products and Services
Strategy Financial Performance